{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:15:48Z","timestamp":1779376548025,"version":"3.53.1"},"reference-count":243,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is one of the most common cancers globally, with nearly 1 million new cases diagnosed annually. It is a complex disease, with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections being the most common etiological factors worldwide. Despite advances in therapy, survival rates for advanced and\/or metastatic HCC remain low, with mortality rates 2.3 times higher in men than women. The liver\u2019s immune system typically maintains an anti-inflammatory environment, contributing to immune tolerance to exogenous, food-derived antigens. However, disruption of the balanced interplay between immune factors within the hepatic microenvironment\u2014due to viral hepatitis, excessive alcohol intake, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)\u2014can lead to chronic inflammation, oxidative stress, a cumulative mutational burden, cirrhosis, and eventually, malignant transformation. Once HCC is established, however, a functional pro-inflammatory immune response becomes critical to controlling tumor progression, as evidenced by the recent success of immune checkpoint inhibitor (ICI) treatments in HCC patients. In addition to ICIs, other novel immunotherapeutic intervention strategies, such as cancer vaccines and adoptive T cell therapies, are currently being investigated. Furthermore, adequate nutrition plays a critical role in modulating immune function, with vitamin D being a key nutrient for immune\/regulation. In this review, we will discuss the potential role of vitamin D in HCC immunity and recent immunotherapeutic advances in the management of this malignancy.<\/jats:p>","DOI":"10.3389\/fnut.2025.1611829","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:20:09Z","timestamp":1758082809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunomodulatory role of vitamin D and emerging immunotherapies in hepatocellular carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Maurizio","family":"Chiriva-Internati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Grizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Noemi","family":"Monari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Daoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Bresalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","author":"Seyhan","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01298-3","article-title":"Liver macrophages: development, dynamics, and functions","author":"Nusse","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.aohep.2019.04.003","article-title":"Immunotherapy in hepatocellular carcinoma","volume":"18","author":"Buonaguro","year":"2019","journal-title":"Ann Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3390\/cancers17111860","article-title":"Bridging immune evasion and vascular dynamics for novel therapeutic frontiers in hepatocellular carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"Cancers"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1080\/21645515.2021.1891817","article-title":"Strategies to sensitize cancer cells to immunotherapy","volume":"17","author":"George","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.26694","article-title":"Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma","volume":"59","author":"Han","year":"2014","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri3044","article-title":"NK cell development, homeostasis and function: parallels with CD8+ T cells","volume":"11","author":"Sun","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-immunol-051116-052415","article-title":"Immune responses in the liver","volume":"36","author":"Kubes","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.55133\/eji.300406","article-title":"Vitamin D and immunity: a comprehensive review of its impact on autoimmunity, allergy suppression, antimicrobial defense, and cancer inhibition","volume":"30","author":"Abo-Zaid","year":"2023","journal-title":"Egypt J Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jsbmb.2013.11.003","article-title":"Is vitamin D deficiency a major global public health problem?","volume":"144","author":"Palacios","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"9016","DOI":"10.3390\/ijms23169016","article-title":"Role of vitamin D in liver disease and complications of advanced chronic liver disease","volume":"23","author":"Ravaioli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"898964","DOI":"10.3389\/fonc.2022.898964","article-title":"Immune checkpoint inhibitors for advanced hepatocellular carcinoma: monotherapies and combined therapies","volume":"12","author":"Ouyang","year":"2022","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3892\/ol.2025.15088","article-title":"Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: a systematic review of current evidence and future prospects (review)","volume":"30","author":"Ma","year":"2025","journal-title":"Oncol Lett"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08830185.2011.646203","article-title":"In this issue: targeting human papilloma virus-associated disease, from cervical to head and neck carcinoma\u2026and more","volume":"31","author":"Chiriva-Internati","year":"2012","journal-title":"Int Rev Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41231-019-0049-0","article-title":"Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy","volume":"4","author":"Mirandola","year":"2019","journal-title":"Transl Med Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e10471","DOI":"10.1371\/journal.pone.0010471","article-title":"Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer","volume":"5","author":"Chiriva-Internati","year":"2010","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1210044","DOI":"10.3389\/fimmu.2023.1210044","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"Buonaguro","year":"2023","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate t cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: then and now","volume":"16","author":"Morse","year":"2021","journal-title":"Target Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat Commun"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1846926","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Onco Targets Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","article-title":"The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity","volume":"29","author":"Zou","year":"2021","journal-title":"Mol Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.immuni.2013.08.036","article-title":"A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4+ T cells","volume":"39","author":"Huang","year":"2013","journal-title":"Immunity"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"334a","DOI":"10.1016\/j.bpj.2021.11.1057","article-title":"Simulating the binding of a t cell receptor to a peptide-bound major histocompatibility complex","volume":"121","author":"Brossard","year":"2022","journal-title":"Biophys J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"245a","DOI":"10.1016\/j.bpj.2019.11.1435","article-title":"Modeling the binding mechanism of a T cell receptor and major histocompatibility complex","volume":"118","author":"Groth","year":"2020","journal-title":"Biophys J"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3390\/cancers15061808","article-title":"Adoptive cell therapy in hepatocellular carcinoma: a review of clinical trials","volume":"15","author":"Ozer","year":"2023","journal-title":"Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1581098","DOI":"10.3389\/fimmu.2025.1581098","article-title":"Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances","volume":"16","author":"Xie","year":"2025","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40364-025-00774-2","article-title":"The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma","volume":"13","author":"Guo","year":"2025","journal-title":"Biomark Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41575-024-00919-y","article-title":"Artificial intelligence in liver cancer\u2014new tools for research and patient management","volume":"21","author":"Calderaro","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41586-018-0519-y","article-title":"Necroptosis microenvironment directs lineage commitment in liver cancer","volume":"562","author":"Seehawer","year":"2018","journal-title":"Nature"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ccell.2017.05.006","article-title":"Kupffer cell-derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS","volume":"31","author":"Yuan","year":"2017","journal-title":"Cancer Cell"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/hep.510270214","article-title":"Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration","volume":"27","author":"Wada","year":"1998","journal-title":"Hepatology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.2174\/138161212802430521","article-title":"Tgfbeta signaling in liver regeneration","volume":"18","author":"Karkampouna","year":"2012","journal-title":"Curr Pharm Des"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1002\/ijc.25920","article-title":"Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice","volume":"129","author":"Zhao","year":"2011","journal-title":"Int J Cancer"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.4049\/jimmunol.1201937","article-title":"Hepatic stellate cells preferentially induce Foxp3+ regulatory t cells by production of retinoic acid","volume":"190","author":"Dunham","year":"2013","journal-title":"J Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/hep.24352","article-title":"Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism","volume":"54","author":"Schildberg","year":"2011","journal-title":"Hepatology"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jhep.2013.04.033","article-title":"Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion","volume":"59","author":"Hochst","year":"2013","journal-title":"J Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1053\/j.gastro.2013.01.021","article-title":"Prognostic gene expression signature for patients with hepatitis c-related early-stage cirrhosis","volume":"144","author":"Hoshida","year":"2013","journal-title":"Gastroenterology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ccr.2006.06.016","article-title":"Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment","volume":"10","author":"Budhu","year":"2006","journal-title":"Cancer Cell"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2019.07.028","article-title":"An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents","volume":"157","author":"Moeini","year":"2019","journal-title":"Gastroenterology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12957-018-1312-y","article-title":"M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4\/STAT3 signaling pathway","volume":"16","author":"Yao","year":"2018","journal-title":"World J Surg Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"6862439","DOI":"10.1155\/2017\/6862439","article-title":"Hepatic immune microenvironment in alcoholic and nonalcoholic liver disease","volume":"2017","author":"Byun","year":"2017","journal-title":"Biomed Res Int"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13046-015-0256-0","article-title":"Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1\/PD-1 signalling pathway in hepatocellular carcinoma","volume":"34","author":"He","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","article-title":"From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma","volume":"38","author":"Fu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3389\/fonc.2019.01146","article-title":"Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4049\/jimmunol.0903275","article-title":"Tim-3\/galectin-9 pathway: regulation of TH1 immunity through promotion of CD11b+Ly-6G+ myeloid cells","volume":"185","author":"Dardalhon","year":"2010","journal-title":"J Immunol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e24671","DOI":"10.1371\/journal.pone.0024671","article-title":"Selective recruitment of regulatory t cell through ccr6-ccl20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00262-019-02427-4","article-title":"Role of regulatory t cells and checkpoint inhibition in hepatocellular carcinoma","volume":"68","author":"Langhans","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/eji.201646559","article-title":"Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver","volume":"46","author":"Harmon","year":"2016","journal-title":"Eur J Immunol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cyto.2006.07.019","article-title":"Changes in hepatic immunoregulatory cytokines in patients with metastatic colorectal carcinoma: implications for hepatic anti-tumour immunity","volume":"35","author":"Kelly","year":"2006","journal-title":"Cytokine"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41590-018-0251-7","article-title":"Metabolic reprogramming of natural killer cells in obesity limits antitumor responses","volume":"19","author":"Michelet","year":"2018","journal-title":"Nat Immunol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/hep.25723","article-title":"Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis c virus infection","volume":"56","author":"Varchetta","year":"2012","journal-title":"Hepatology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3389\/fimmu.2018.01808","article-title":"The paradoxical role of NKG2D in cancer immunity","volume":"9","author":"Sheppard","year":"2018","journal-title":"Front Immunol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13046-014-0076-7","article-title":"MICA\/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma","volume":"33","author":"Fang","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jhep.2011.06.017","article-title":"Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence","volume":"56","author":"Kamimura","year":"2012","journal-title":"J Hepatol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating t cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s40425-019-0814-7","article-title":"PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma","volume":"7","author":"Ma","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.18632\/oncotarget.27146","article-title":"Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma","volume":"10","author":"Tauber","year":"2019","journal-title":"Oncotarget"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"J Hepatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/ni.3290","article-title":"Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma","volume":"16","author":"Finkin","year":"2015","journal-title":"Nat Immunol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0782","article-title":"Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment","volume":"4","author":"Horwitz","year":"2014","journal-title":"Cancer Discov"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/nu14030473","article-title":"The immunologic profile of vitamin D and its role in different immune-mediated diseases: an expert opinion","volume":"14","author":"Giannini","year":"2022","journal-title":"Nutrients"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01635581.2020.1797127","article-title":"Serum vitamin D levels and risk of liver cancer: a systematic review and dose-response meta-analysis of cohort studies","volume":"73","author":"Zhang","year":"2020","journal-title":"Nutr Cancer"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s10620-023-07931-3","article-title":"Activation of vitamin D\/VDR signaling reverses gemcitabine resistance of pancreatic cancer cells through inhibition of MUC1 expression","volume":"68","author":"Wei","year":"2023","journal-title":"Dig Dis Sci"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112716","article-title":"Vitamin D: promises on the horizon and challenges ahead for fighting pancreatic cancer","volume":"13","author":"Wei","year":"2021","journal-title":"Cancers"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/gutjnl-2017-315242","article-title":"Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial","volume":"68","author":"Crockett","year":"2019","journal-title":"Gut"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1500409","article-title":"A trial of calcium and vitamin D for the prevention of colorectal adenomas","volume":"373","author":"Baron","year":"2015","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/cid\/cit549","article-title":"Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial","volume":"57","author":"Rees","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bju.16443","article-title":"Preliminary findings on vitamin D 25-OH levels in urine analysis: implications for clinical practice","volume":"134","author":"Piccolini","year":"2024","journal-title":"BJU Int"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/bs.afnr.2023.12.004","article-title":"Vitamin D and celiac disease","volume":"109","author":"Trasciatti","year":"2024","journal-title":"Adv Food Nutr Res"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3390\/ijms26104511","article-title":"Vitamin D and immune checkpoint inhibitors in lung cancer: a synergistic approach to enhancing treatment efficacy","volume":"26","author":"Zhang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pedneo.2019.04.007","article-title":"Vitamin D and health\u2014the missing vitamin in humans","volume":"60","author":"Chang","year":"2019","journal-title":"Pediatr Neonatol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"e10405","DOI":"10.1002\/jbm4.10405","article-title":"Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory","volume":"5","author":"Bishop","year":"2021","journal-title":"JBMR Plus"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"ref94","first-page":"S57","article-title":"The vitamin D hormone and its nuclear receptor: molecular actions and disease states","volume":"154","author":"Haussler","year":"1997","journal-title":"J Endocrinol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1093\/jn\/134.12.3215","article-title":"Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean?","volume":"134","author":"Fleet","year":"2004","journal-title":"J Nutr"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jsbmb.2014.11.002","article-title":"Membrane-mediated actions of 1,25-dihydroxy vitamin D3: a review of the roles of phospholipase A2 activating protein and Ca2+\/calmodulin-dependent protein kinase II","volume":"147","author":"Doroudi","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cellsig.2009.11.009","article-title":"A role for the phosphatidylinositol 3-kinase--protein kinase C zeta--Sp1 pathway in the 1,25-dihydroxyvitamin D3 induction of the 25-hydroxyvitamin D3 24-hydroxylase gene in human kidney cells","volume":"22","author":"Dwivedi","year":"2010","journal-title":"Cell Signal"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1210\/en.2006-0946","article-title":"Minireview: vitamin D receptor: new assignments for an already busy receptor","volume":"147","author":"Norman","year":"2006","journal-title":"Endocrinology"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/MEG.0000000000001597","article-title":"Vitamin D-related immunomodulation in patients with liver cirrhosis","volume":"32","author":"Triantos","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.3390\/ijms25094901","article-title":"Vitamin D and metabolic dysfunction-associated steatotic liver disease (MASLD): novel mechanistic insights","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"991","DOI":"10.31557\/APJCP.2021.22.4.991","article-title":"Effect of vitamin D deficiency on liver cancer risk: a systematic review and meta-analysis","volume":"22","author":"Yi","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/gutjnl-2014-307024","article-title":"Vitamin D counteracts fibrogenic TGF-\u03b2 signalling in human hepatic stellate cells both receptor-dependently and independently","volume":"64","author":"Beilfuss","year":"2015","journal-title":"Gut"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"10990","DOI":"10.1073\/pnas.92.24.10990","article-title":"Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3","volume":"92","author":"Yu","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/carcin\/bgl041","article-title":"1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis","volume":"27","author":"Bao","year":"2006","journal-title":"Carcinogenesis"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.3390\/nu5103993","article-title":"Molecular link between vitamin D and cancer prevention","volume":"5","author":"Moukayed","year":"2013","journal-title":"Nutrients"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.3390\/molecules25143219","article-title":"Vitamin D signaling in inflammation and cancer: molecular mechanisms and therapeutic implications","volume":"25","author":"El-Sharkawy","year":"2020","journal-title":"Molecules"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.4049\/jimmunol.0803736","article-title":"Vitamin D-directed rheostatic regulation of monocyte antibacterial responses","volume":"182","author":"Adams","year":"2009","journal-title":"J Immunol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.1123933","article-title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response","volume":"311","author":"Liu","year":"2006","journal-title":"Science"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2310\/JIM.0b013e31821b8755","article-title":"Vitamin D and the immune system","volume":"59","author":"Aranow","year":"2011","journal-title":"J Investig Med"},{"key":"ref111","first-page":"5624","article-title":"Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues","volume":"44","author":"Koeffler","year":"1984","journal-title":"Cancer Res"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.4049\/jimmunol.1400698","article-title":"The effects of 1,25-dihydroxyvitamin D3 on in vitro human NK cell development from hematopoietic stem cells","volume":"193","author":"Weeres","year":"2014","journal-title":"J Immunol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1002\/eji.201545541","article-title":"1,25-dihydroxy-vitamin D3 regulates NK-cell cytotoxicity, cytokine secretion, and degranulation in women with recurrent pregnancy losses","volume":"45","author":"Ota","year":"2015","journal-title":"Eur J Immunol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1017\/S0029665111003193","article-title":"Vitamin D, invariant natural killer t-cells and experimental autoimmune disease","volume":"71","author":"Cantorna","year":"2012","journal-title":"Proc Nutr Soc"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1704S","DOI":"10.1093\/jn\/125.suppl_6.1704S","article-title":"Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of th1 functions","volume":"125","author":"Lemire","year":"1995","journal-title":"J Nutr"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.4049\/jimmunol.167.9.4974","article-title":"1alpha,25-dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of th2 cells","volume":"167","author":"Boonstra","year":"2001","journal-title":"J Immunol"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.4049\/jimmunol.0801543","article-title":"Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response","volume":"182","author":"Tang","year":"2009","journal-title":"J Immunol"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.mce.2010.02.013","article-title":"Vitamin D and the intracrinology of innate immunity","volume":"321","author":"Hewison","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12865-014-0035-2","article-title":"Vitamin D-binding protein controls T cell responses to vitamin D","volume":"15","author":"Kongsbak","year":"2014","journal-title":"BMC Immunol"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fimmu.2013.00148","article-title":"The vitamin D receptor and T cell function","volume":"4","author":"Kongsbak","year":"2013","journal-title":"Front Immunol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3109\/10408363.2015.1094443","article-title":"Role of vitamin D in cytotoxic T lymphocyte immunity to pathogens and cancer","volume":"53","author":"Sarkar","year":"2016","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"7708","DOI":"10.1038\/s41598-018-26064-6","article-title":"Vitamin D levels correlate with lymphocyte subsets in elderly patients with age-related diseases","volume":"8","author":"Mao","year":"2018","journal-title":"Sci Rep"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-3-540-71029-5_12","article-title":"Induction of tolerogenic dendritic cells by vitamin D receptor agonists","volume":"188","author":"Adorini","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","article-title":"Tolerogenic dendritic cells","volume":"21","author":"Steinman","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.4049\/jimmunol.0803345","article-title":"1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype","volume":"182","author":"Szeles","year":"2009","journal-title":"J Immunol"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.4049\/jimmunol.164.9.4443","article-title":"Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells","volume":"164","author":"Piemonti","year":"2000","journal-title":"J Immunol"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1172\/JCI32354","article-title":"Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function","volume":"119","author":"Urry","year":"2009","journal-title":"J Clin Invest"},{"key":"ref128","first-page":"965","article-title":"Current status in vitamin D and regulatory T cells\u2014immunological implications","volume":"117","author":"Mocanu","year":"2013","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2337\/diabetes.51.5.1367","article-title":"A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory t-cells and arrests autoimmune diabetes in nod mice","volume":"51","author":"Gregori","year":"2002","journal-title":"Diabetes"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.4049\/jimmunol.0803217","article-title":"1,25-dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and Foxp3","volume":"183","author":"Jeffery","year":"2009","journal-title":"J Immunol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/rheumatology\/keq124","article-title":"Vitamin D3 down-regulates intracellular toll-like receptor 9 expression and toll-like receptor 9-induced il-6 production in human monocytes","volume":"49","author":"Dickie","year":"2010","journal-title":"Rheumatology"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.1158\/0008-5472.CAN-05-1435","article-title":"Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells","volume":"65","author":"Moreno","year":"2005","journal-title":"Cancer Res"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1210\/en.2009-0855","article-title":"Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy","volume":"151","author":"Krishnan","year":"2010","journal-title":"Endocrinology"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.3892\/or.2012.2031","article-title":"1,25-dihydroxyvitamin D3 inhibits growth of the breast cancer cell line MCF-7 and downregulates cytochrome P4501B1 through the COX-2\/PGE2 pathway","volume":"28","author":"Yuan","year":"2012","journal-title":"Oncol Rep"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/nar\/gkj460","article-title":"Regulation of the human p21(waf1\/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor","volume":"34","author":"Saramaki","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1101\/gad.10.2.142","article-title":"Transcriptional activation of the CDK inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937","volume":"10","author":"Liu","year":"1996","journal-title":"Genes Dev"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/ijms19061618","article-title":"Role of vitamin D beyond the skeletal function: a review of the molecular and clinical studies","volume":"19","author":"Umar","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"25260","DOI":"10.1074\/jbc.M311052200","article-title":"P27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin e\/cyclin-dependent kinase 2 and skp1-cullin-f-box protein\/skp2 ubiquitin ligase","volume":"279","author":"Li","year":"2004","journal-title":"J Biol Chem"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/187152013804487443","article-title":"The anti-cancer actions of vitamin D","volume":"13","author":"Chiang","year":"2013","journal-title":"Anti Cancer Agents Med Chem"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"581S","DOI":"10.1093\/jn\/129.2.581S","article-title":"Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation","volume":"129","author":"Freedman","year":"1999","journal-title":"J Nutr"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1053\/j.gastro.2012.05.043","article-title":"Dysregulated Kruppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma","volume":"143","author":"Li","year":"2012","journal-title":"Gastroenterology"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/1078-0432.CCR-15-0528","article-title":"Kruppel-like factor 4 blocks hepatocellular carcinoma dedifferentiation and progression through activation of hepatocyte nuclear factor-6","volume":"22","author":"Sun","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"1106952","DOI":"10.3389\/fgene.2023.1106952","article-title":"Klf4 loss in hepatocellular carcinoma: improving prognostic prediction and correlating immune infiltrates","volume":"14","author":"Chen","year":"2023","journal-title":"Front Genet"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1038\/onc.2016.447","article-title":"Loss of KLF4 and consequential downregulation of SMAD7 exacerbate oncogenic TGF-beta signaling in and promote progression of hepatocellular carcinoma","volume":"36","author":"Sun","year":"2017","journal-title":"Oncogene"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"15566","DOI":"10.18632\/aging.103592","article-title":"The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection","volume":"12","author":"Xue","year":"2020","journal-title":"Aging"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/cancers5041242","article-title":"Vitamin D is a multilevel repressor of Wnt\/b-catenin signaling in cancer cells","volume":"5","author":"Larriba","year":"2013","journal-title":"Cancers"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.molcel.2006.01.037","article-title":"The molecular basis of vitamin D receptor and beta-catenin crossregulation","volume":"21","author":"Shah","year":"2006","journal-title":"Mol Cell"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1097\/MIB.0000000000001209","article-title":"E-cadherin mediates the preventive effect of vitamin D3 in colitis-associated carcinogenesis","volume":"23","author":"Xin","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/carcin\/bgm094","article-title":"The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells","volume":"28","author":"Aguilera","year":"2007","journal-title":"Carcinogenesis"},{"key":"ref150","first-page":"2304","article-title":"Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy","volume":"60","author":"Diaz","year":"2000","journal-title":"Cancer Res"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0960-0760(96)00048-9","article-title":"Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells","volume":"58","author":"James","year":"1996","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3109\/13880209.2014.988274","article-title":"Vitamin D in cancer chemoprevention","volume":"53","author":"Giammanco","year":"2015","journal-title":"Pharm Biol"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"9101","DOI":"10.1074\/jbc.M006876200","article-title":"Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells","volume":"276","author":"Narvaez","year":"2001","journal-title":"J Biol Chem"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0960-0760(96)00055-6","article-title":"1,25-dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells","volume":"58","author":"Simboli-Campbell","year":"1996","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref155","first-page":"667","article-title":"Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer","volume":"1","author":"Guzey","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1210\/endo.141.1.7289","article-title":"Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of bcl-2","volume":"141","author":"Blutt","year":"2000","journal-title":"Endocrinology"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.4161\/cc.9.15.12381","article-title":"Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system","volume":"9","author":"Yu","year":"2010","journal-title":"Cell Cycle"},{"key":"ref158","first-page":"1043","article-title":"Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis","volume":"7","author":"Hershberger","year":"2001","journal-title":"Clin Cancer Res"},{"key":"ref159","first-page":"821","article-title":"Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression","volume":"1","author":"Hershberger","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"ref160","first-page":"4164","article-title":"Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk\/Akt signaling","volume":"7","author":"Bernardi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3892\/ijmm.2014.1664","article-title":"1,25-dihydroxyvitamin D(3) and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells","volume":"33","author":"Bao","year":"2014","journal-title":"Int J Mol Med"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/sj.embor.7400594","article-title":"Convergence of vitamin D and retinoic acid signalling at a common hormone response element","volume":"7","author":"Tavera-Mendoza","year":"2006","journal-title":"EMBO Rep"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1158\/1535-7163.MCT-06-0316","article-title":"Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery","volume":"5","author":"Demasters","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.4161\/15548627.2014.993283","article-title":"A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089","volume":"10","author":"Sharma","year":"2014","journal-title":"Autophagy"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7150\/jca.1.101","article-title":"Vitamin D in combination cancer treatment","volume":"1","author":"Ma","year":"2010","journal-title":"J Cancer"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0090-4295(97)00408-1","article-title":"Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the dunning rat prostate model system","volume":"50","author":"Getzenberg","year":"1997","journal-title":"Urology"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/carcin\/bgh332","article-title":"1 alpha,25-dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer","volume":"26","author":"Nakagawa","year":"2005","journal-title":"Carcinogenesis"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/0008-5472.CAN-08-2307","article-title":"Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo","volume":"69","author":"Chung","year":"2009","journal-title":"Cancer Res"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.2174\/09298673113209990248","article-title":"Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery","volume":"20","author":"Guo","year":"2013","journal-title":"Curr Med Chem"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.4049\/jimmunol.1000990","article-title":"Vitamin D3 upregulated protein 1 suppresses TNF-\u03b1-induced NF-\u03baB activation in hepatocarcinogenesis","volume":"185","author":"Kwon","year":"2010","journal-title":"J Immunol"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jsbmb.2004.03.068","article-title":"Anti-tumor activity of calcitriol: pre-clinical and clinical studies","volume":"89","author":"Trump","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.adh7954","article-title":"Vitamin D regulates microbiome-dependent cancer immunity","volume":"384","author":"Giampazolias","year":"2024","journal-title":"Science"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/1097-0142(20010615)91:12<2431::AID-CNCR1278>3.0.CO;2-3","article-title":"A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation","volume":"91","author":"Beer","year":"2001","journal-title":"Cancer"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1158\/1078-0432.CCR-06-1165","article-title":"A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors","volume":"13","author":"Fakih","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref175","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00280-009-1000-2","article-title":"A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors","volume":"65","author":"Muindi","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/sj.bjc.6600162","article-title":"A phase II trial of the vitamin D analogue seocalcitol (EB1089) in patients with inoperable pancreatic cancer","volume":"86","author":"Evans","year":"2002","journal-title":"Br J Cancer"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/bjc.1998.434","article-title":"A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer","volume":"78","author":"Gulliford","year":"1998","journal-title":"Br J Cancer"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/sj.bjc.6601104","article-title":"A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma","volume":"89","author":"Dalhoff","year":"2003","journal-title":"Br J Cancer"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/jco.2003.05.117","article-title":"Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer","volume":"21","author":"Beer","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ascent investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis c","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"ref182","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1073\/pnas.1718217115","article-title":"Role of PD-1 during effector CD8 T cell differentiation","volume":"115","author":"Ahn","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (checkmate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (keynote-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/1940-6207.CAPR-10-0040","article-title":"Vaccine prevention of cancer: can endogenous antigens be targeted?","volume":"3","author":"Weiner","year":"2010","journal-title":"Cancer Prev Res"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"9039","DOI":"10.7314\/apjcp.2014.15.20.9039","article-title":"Immunopreventive effects against murine h22 hepatocellular carcinoma in vivo by a DNA vaccine targeting a gastrin-releasing peptide","volume":"15","author":"Meko\u2019o","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3892\/or.2012.2130","article-title":"Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model","volume":"29","author":"Kwon","year":"2013","journal-title":"Oncol Rep"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-021-01467-8","article-title":"Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion","volume":"20","author":"Cai","year":"2021","journal-title":"Mol Cancer"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nri1150","article-title":"Cancer vaccines: between the idea and the reality","volume":"3","author":"Finn","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1471-2407-10-209","article-title":"A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma","volume":"10","author":"Greten","year":"2010","journal-title":"BMC Cancer"},{"key":"ref196","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-21-4424","article-title":"Phase I\/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma","volume":"28","author":"Loffler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1034\/j.1600-065x.2002.18816.x","article-title":"Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes","volume":"188","author":"Melief","year":"2002","journal-title":"Immunol Rev"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref200","first-page":"111","article-title":"Diverse efficacy of vaccination therapy using the alpha-fetoprotein gene against mouse hepatocellular carcinoma","volume":"13","author":"Saeki","year":"2004","journal-title":"Int J Mol Med"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"008","DOI":"10.17352\/2455-8591.000037","article-title":"The potential of mRNA vaccine in HCC treatment","volume":"9","author":"Rui","year":"2023","journal-title":"Int J Immunother Cancer Res"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"1081572","DOI":"10.3389\/fimmu.2023.1081572","article-title":"Alpha fetoprotein promotes polarization of macrophages towards M2-like phenotype and inhibits macrophages to phagocytize hepatoma cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3892\/ijo.2012.1626","article-title":"Phase I\/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma","volume":"41","author":"Tada","year":"2012","journal-title":"Int J Oncol"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/bjc.2015.430","article-title":"A phase I\/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma","volume":"113","author":"Lee","year":"2015","journal-title":"Br J Cancer"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"e1328335","DOI":"10.1080\/2162402X.2017.1328335","article-title":"Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study","volume":"6","author":"Lee","year":"2017","journal-title":"Onco Targets Ther"},{"key":"ref206","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/hep.22626","article-title":"A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma","volume":"49","author":"Palmer","year":"2009","journal-title":"Hepatology"},{"key":"ref207","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jcyt.2018.06.002","article-title":"Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis","volume":"20","author":"Chen","year":"2018","journal-title":"Cytotherapy"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"key":"ref209","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"key":"ref210","doi-asserted-by":"publisher","first-page":"41339","DOI":"10.18632\/oncotarget.5463","article-title":"A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"Nk cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"ref212","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nri3065","article-title":"Organ-specific features of natural killer cells","volume":"11","author":"Shi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"ref213","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s13277-015-3845-9","article-title":"Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma","volume":"37","author":"Sun","year":"2016","journal-title":"Tumour Biol"},{"key":"ref214","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol Int"},{"key":"ref215","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonzalez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"ref216","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/hep4.1857","article-title":"Immunological alterations after immunotherapy with short lived HBV-TCR t cells associates with long-term treatment response in HBV-HCC","volume":"6","author":"Tan","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref217","doi-asserted-by":"publisher","first-page":"eaaz3223","DOI":"10.1126\/sciadv.aaz3223","article-title":"Chimeric antigen receptor signaling: functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Sci Adv"},{"key":"ref218","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering car-t cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"ref219","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"ref220","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","article-title":"CAR-T cells inflict sequential killing of multiple tumor target cells","volume":"3","author":"Davenport","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"ref221","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-12-2616","article-title":"First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref222","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acs.molpharmaceut.5b00132","article-title":"Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy","volume":"12","author":"Hanaoka","year":"2015","journal-title":"Mol Pharm"},{"key":"ref223","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2019.00248","article-title":"Next-generation cancer immunotherapy targeting glypican-3","volume":"9","author":"Shimizu","year":"2019","journal-title":"Front Oncol"},{"key":"ref224","doi-asserted-by":"publisher","first-page":"824208","DOI":"10.3389\/fonc.2022.824208","article-title":"Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Oncol"},{"key":"ref225","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref226","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2004.06.018","article-title":"A direct role for NKG2D\/MICA interaction in villous atrophy during celiac disease","volume":"21","author":"Hue","year":"2004","journal-title":"Immunity"},{"key":"ref227","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/0008-5472.CAN-07-6013","article-title":"EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma","volume":"68","author":"Yamashita","year":"2008","journal-title":"Cancer Res"},{"key":"ref228","doi-asserted-by":"publisher","first-page":"751.e1","DOI":"10.1016\/j.jtct.2022.08.001","article-title":"Vitamin D insufficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"28","author":"Nath","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref229","doi-asserted-by":"publisher","first-page":"1076883","DOI":"10.3389\/fimmu.2022.1076883","article-title":"Advances in artificial intelligence to predict cancer immunotherapy efficacy","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"ref230","doi-asserted-by":"publisher","first-page":"1176935119852081","DOI":"10.1177\/1176935119852081","article-title":"Machine learning-enhanced T cell neoepitope discovery for immunotherapy design","volume":"18","author":"Martins","year":"2019","journal-title":"Cancer Inform"},{"key":"ref231","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1039\/c7lc00955k","article-title":"Machine learning to detect signatures of disease in liquid biopsies\u2014a user\u2019s guide","volume":"18","author":"Ko","year":"2018","journal-title":"Lab Chip"},{"key":"ref232","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1016\/j.jtho.2019.05.021","article-title":"Immunotherapy combinations in patients with small cell lung cancers","volume":"14","author":"Yan","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref233","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1102\/1470-7330.2005.0018","article-title":"Computer aided detection (CAD): an overview","volume":"5","author":"Castellino","year":"2005","journal-title":"Cancer Imaging"},{"key":"ref234","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/neuonc\/noz184","article-title":"Automated machine learning based on radiomics features predicts H3 K27M mutation in midline gliomas of the brain","volume":"22","author":"Su","year":"2020","journal-title":"Neuro-Oncol"},{"key":"ref235","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jamaoncol.2016.2631","article-title":"The potential of radiomic-based phenotyping in precision medicine: a review","volume":"2","author":"Aerts","year":"2016","journal-title":"JAMA Oncol"},{"key":"ref236","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol"},{"key":"ref237","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"ref238","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J Hepatol"},{"key":"ref239","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","article-title":"Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy","volume":"5","author":"Li","year":"2024","journal-title":"Nat Cancer"},{"key":"ref240","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"ref241","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Celsa","year":"2024","journal-title":"J Hepatol"},{"key":"ref242","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.stem.2022.04.006","article-title":"Patient-derived micro-organospheres enable clinical precision oncology","volume":"29","author":"Ding","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref243","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ccell.2022.09.017","article-title":"A path to translation: how 3D patient tumor avatars enable next generation precision oncology","volume":"40","author":"Bose","year":"2022","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1611829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:20:13Z","timestamp":1758082813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1611829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":243,"alternative-id":["10.3389\/fnut.2025.1611829"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2025.1611829","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1611829"}}